EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 365 filers reported holding EXELIXIS INC in Q1 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $4,000 | +33.3% | 242 | +70.4% | 0.00% | – |
| Q3 2021 | $3,000 | 0.0% | 142 | 0.0% | 0.00% | – |
| Q2 2021 | $3,000 | -66.7% | 142 | -65.3% | 0.00% | – |
| Q1 2021 | $9,000 | -99.8% | 409 | -99.8% | 0.00% | -100.0% |
| Q2 2020 | $4,924,000 | +1569.2% | 207,432 | +1140.9% | 0.01% | +800.0% |
| Q1 2020 | $295,000 | -13.7% | 16,716 | -13.8% | 0.00% | 0.0% |
| Q4 2019 | $342,000 | +27.6% | 19,398 | +30.2% | 0.00% | – |
| Q3 2019 | $268,000 | +3.1% | 14,903 | +22.5% | 0.00% | – |
| Q2 2019 | $260,000 | -46.2% | 12,167 | -40.0% | 0.00% | -100.0% |
| Q1 2019 | $483,000 | +22.6% | 20,276 | +1.2% | 0.00% | 0.0% |
| Q4 2018 | $394,000 | -42.5% | 20,045 | -48.1% | 0.00% | 0.0% |
| Q3 2018 | $685,000 | +11.2% | 38,635 | +38.9% | 0.00% | 0.0% |
| Q1 2018 | $616,000 | -3.8% | 27,814 | +32.1% | 0.00% | 0.0% |
| Q4 2017 | $640,000 | +91.6% | 21,048 | +52.7% | 0.00% | 0.0% |
| Q3 2017 | $334,000 | – | 13,785 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |